Topas Therapeutics GmbH (Topas), today announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris (PV), an orphan autoimmune disease. TPM203 is Topas’ most advanced program and the first one from the Company’s proprietary Topas Particle Conjugates (TPC) platform technology to enter the clinic.
PRESS RELEASES & ARTICLES
STAY UPDATED
Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
December 18, 2019
PDF
Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio
September 24, 2019
Amphivena Therapeutics, Inc., announced today the closing of a $62 million Series C financing. The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and insiders MPM Capital, funds managed by Tekla Capital Management LLC and Franklin Berger.
Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey
September 12, 2019
Crescendo Biologics Ltd (Crescendo) today announces that it has signed collaborations with world-renowned oncology research groups at the University of Oxford and the University of Surrey. These collaborations will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow-on pipeline of CD137-directed T cell enhancing programmes.
Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
August 28, 2019
PDFImmatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients
July 19, 2019
PDFImmatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers
April 09, 2019
PDFImmatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
February 26, 2019
PDFUS Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
January 03, 2019
PDFNature publication reports first-in-human trial for a personalized cancer immunotherapy
December 20, 2018
PDFOpsona Therapeutics to present results on Tomaralimab study at the 60th Annual Meeting of the American Society of Hematology (ASH)
October 25, 2018
PDFEMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) Transaction.
September 13, 2018
PDFTopas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund
November 02, 2017
PDFImmatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
October 04, 2017
PDFCrescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards
June 16, 2017
PDF